![new life program 253 new life program 253](http://www.lookze.com/photos/346_Broadway_g.jpg)
![new life program 253 new life program 253](https://news.mit.edu/sites/default/files/images/201608/MIT-Program-Switch.jpg)
Shekari et al., Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution (Poster #P2-253, 12:00am - 11:59pm)ĪMYPAD virtual featured research session “Progressing the clinical and technical value of amyloid PET in dementia – the AMYPAD experience”.
![new life program 253 new life program 253](https://www.commhealth.org/wp-content/uploads/D8P_8863.jpg)
Holy et al., Non-invasive quantification and SUVR validation of -florbetaben with total-body EXPLORER PET (Poster #P2-213, 12:00am - 11:59pm).
![new life program 253 new life program 253](https://3.files.edl.io/7f38/20/10/19/202215-3ba0af60-f206-4f31-972e-77cef4cd3b93.jpg)
New life program 253 plus#
Hönig et al., Inverse relationship between education and amyloid burden in individuals with subjective cognitive decline plus and mild cognitive impairment (Virtual Poster, 7:00am - 11:55pm).Holy et al., Non-invasive quantification and SUVR validation of -florbetaben with total-body EXPLORER PET (Oral #IC_O-07-03, Ballroom 20D - San Diego Convention Center, 2:40pm - 2:55pm)."PET Neuroimaging is broadly expanding, revealing new insights into pathophysiology and providing important biomarker data for diagnosing patients and in therapeutic clinical trials.”ĭatasets involving LMI compounds presented at the AAIC conference include the following presentations:Īmyloid-PET Neuroimaging presentations involving Neuraceq® (florbetaben F18 injection): Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. "We are impressed by the data that research groups around the world have collected over the last year," said Dr. LMI in conjunction with Clario will host a reception and presentations of tau PET imaging, quantification and use in clinical trials featuring Dr. A virtual featured research session entitled “Progressing the clinical and technical value of amyloid PET in dementia – the AMYPAD experience” will be held on August 1st. LMI is also proud to be contributing with The Amyloid imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative to the AAIC program. The contributions cover twelve (12) presentations demonstrating the utility of its approved compound Neuraceq® (florbetaben F18 injection), thirteen (13) presentations supporting the potential of its investigational tau tracer 18F-PI-2620 and one (1) presentation highlighting first-in-human data from its investigational neuroinflammation imaging tracer 18F-DED. Life Molecular Imaging (LMI) announces today that new research results on its approved and investigational positron emission tomography (PET) neuroimaging tracers will be presented at the Alzheimer’s Imaging Consortium (AIC) meeting and the Alzheimer’s Association International Conference (AAIC) in San Diego (July 30 – August 4, 2022), the biggest and most influential international meeting dedicated to advancing dementia science.